Welcome to our dedicated page for ALLURION TECHNOLOGIES news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on ALLURION TECHNOLOGIES stock.
Allurion Technologies, Inc. develops a weight-loss platform centered on the Allurion Program, which combines the FDA PMA approved Allurion Gastric Balloon System featuring the Allurion Smart Capsule with a Virtual Care Suite that includes the Allurion Mobile App, Iris AI, Allurion Insights and the Allurion Connected Scale.
Company news centers on U.S. commercialization of the Allurion Smart Capsule, FDA regulatory status, provider training and commercial account onboarding, obesity-care partnerships and use of the program alongside GLP-1 therapies. Updates also cover preliminary operating results, balance-sheet and warrant-related capital actions, and listing-compliance matters involving Allurion common stock and warrants.
Allurion (OTCQB: ALUR) approved a 1-for-15 reverse stock split of its common stock, aimed at supporting compliance for a potential NYSE or NYSE American listing and advancing its re-listing strategy.
The split is effective June 18, 2026, reducing outstanding shares from about 15.0M to 1.0M, with temporary symbol ALURD for 20 days and proportional adjustments to equity awards, notes, and warrants.
Allurion (OTCQB: ALUR) reported a strong start to its U.S. launch of the Allurion Program and Smart Capsule. Early patients lost 8–11% of total body weight in four weeks, most after discontinuing GLP-1 drugs.
The company cites rapid commercial momentum, with U.S. revenue on track to double this quarter, treatment sessions expected to quadruple, robust re-order rates, ASP and gross margins above plan, and the first U.S. launch quarter projected to be profitable.
Allurion (OTCID: ALUR) treated its first commercial patients in the United States on April 20, 2026, marking its U.S. commercial launch. The company positions the Allurion Smart Capsule as a non-surgical, non-pharmaceutical weight-loss option delivering fast results with placement in about 15 minutes and no endoscopy or anesthesia.
Early patient demand includes people discontinuing GLP-1 therapy; Allurion is expanding clinical centers and exploring partnerships with self-insured employers to broaden access.
Allurion (OTCID: ALUR) has appealed the New York Stock Exchange decision to initiate delisting proceedings under Section 802.01B, which requires a 30-day average global market capitalization of at least $15,000,000. The company plans to regain NYSE compliance or relist on the NYSE American after its FDA approval of the Allurion Gastric Balloon System on February 20, 2026.
Allurion says it will strengthen the balance sheet and fund U.S. commercialization; securities currently trade on the OTCID market while the plan is executed. No assurance of success was stated.
Allurion (OTCID: ALUR) has begun U.S. training and on-boarding of partner accounts and started manufacturing its FDA-approved product, with first shipments expected in April 2026. The launch targets patients who started then stopped GLP-1s and explores employer partnerships to broaden benefit coverage.
The company expects U.S. availability to expand through 2026 as additional partners complete training and begin offering the Allurion Program in clinical settings nationwide.
Allurion (NYSE: ALUR) received a NYSE notice initiating delisting proceedings for failure to meet Section 802.01B listing standards. The company intends to appeal and expects its common stock to continue trading on the NYSE during the review.
Allurion cited FDA approval on February 20, 2026 as the first step in a plan to regain compliance or relist, and referenced creditor negotiations, a previously announced debt-for-preferred exchange agreement, and a warrant inducement completed February 24, 2026 as part of its remediation efforts.
Allurion (NYSE: ALUR) entered a definitive agreement to effect immediate exercise of outstanding warrants for aggregate proceeds of approximately $3.0 million at a reduced exercise price of $1.15 per share. The exercise covers 2,659,565 existing warrants with closing expected on or about February 25, 2026.
In consideration, holders will receive new private-placement warrants exercisable into up to 5,319,130 shares, subject to stockholder approval and resale registration; Roth Capital Partners is financial advisor.
Allurion (NYSE: ALUR) received U.S. FDA premarket approval on February 23, 2026 for the Allurion Gastric Balloon System featuring the Allurion Smart Capsule.
The non-surgical, 15-minute orally administered device resides ~4 months in the stomach, is repeatable, and targets adults with BMI 30–40, opening access to ~80 million Americans with obesity.
Allurion (NYSE: ALUR) announced a partnership with Bionut and pharmacy partner Farmastar in Argentina to offer discounted Mounjaro (tirzepatide) for use with the Allurion Smart Capsule, expanding access to combination therapy.
Reported clinical results in 76 patients showed 23% average total body weight loss at 12 months, a 14% point increase in lean body mass share (62% to 70%), full adherence and no early discontinuations while using low doses (2.5–5.0 mg) of tirzepatide.
Allurion (NYSE: ALUR) announced preliminary, unaudited results for Q4 and full-year 2025. Management expects Q4 revenue of $3.3M–$3.7M, representing a 22%–37% quarter-over-quarter increase, and full-year revenue of approximately $15M. The company reported continued, substantial improvement in operating expenses and operating loss both quarter-over-quarter and versus the prior year. Management highlighted that a new commercial strategy implemented after a 2025 strategic pivot contributed to the quarter's revenue growth and said a potential FDA approval of the Allurion Smart Capsule is possible in 2026.